GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » VentriPoint Diagnostics Ltd (TSXV:VPT) » Definitions » Debt-to-Equity

VentriPoint Diagnostics (TSXV:VPT) Debt-to-Equity : 2.17 (As of Dec. 2023)


View and export this data going back to 2005. Start your Free Trial

What is VentriPoint Diagnostics Debt-to-Equity?

VentriPoint Diagnostics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was C$0.12 Mil. VentriPoint Diagnostics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was C$0.30 Mil. VentriPoint Diagnostics's Total Stockholders Equity for the quarter that ended in Dec. 2023 was C$0.19 Mil. VentriPoint Diagnostics's debt to equity for the quarter that ended in Dec. 2023 was 2.17.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for VentriPoint Diagnostics's Debt-to-Equity or its related term are showing as below:

TSXV:VPT' s Debt-to-Equity Range Over the Past 10 Years
Min: -2.22   Med: -0.31   Max: 2.17
Current: 2.17

During the past 13 years, the highest Debt-to-Equity Ratio of VentriPoint Diagnostics was 2.17. The lowest was -2.22. And the median was -0.31.

TSXV:VPT's Debt-to-Equity is ranked worse than
95.87% of 702 companies
in the Medical Devices & Instruments industry
Industry Median: 0.22 vs TSXV:VPT: 2.17

VentriPoint Diagnostics Debt-to-Equity Historical Data

The historical data trend for VentriPoint Diagnostics's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

VentriPoint Diagnostics Debt-to-Equity Chart

VentriPoint Diagnostics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.46 -0.58 0.02 0.10 2.17

VentriPoint Diagnostics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.10 0.14 0.19 0.33 2.17

Competitive Comparison of VentriPoint Diagnostics's Debt-to-Equity

For the Medical Devices subindustry, VentriPoint Diagnostics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


VentriPoint Diagnostics's Debt-to-Equity Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, VentriPoint Diagnostics's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where VentriPoint Diagnostics's Debt-to-Equity falls into.



VentriPoint Diagnostics Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

VentriPoint Diagnostics's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

VentriPoint Diagnostics's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


VentriPoint Diagnostics  (TSXV:VPT) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.


Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.


VentriPoint Diagnostics Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of VentriPoint Diagnostics's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


VentriPoint Diagnostics (TSXV:VPT) Business Description

Traded in Other Exchanges
Address
18 Hook Avenue, Unit 101, Toronto, ON, CAN, M6P 1T4
VentriPoint Diagnostics Ltd is a medical device company engaged in the development and commercialization of diagnostic tools that monitor patients with heart disease. It develops applications for heart diseases and imaging modalities which includes congenital heart disease, left or right heart failure, and normal hearts. It sells its products in Canada and internationally.
Executives
Robert Hodgkinson Director

VentriPoint Diagnostics (TSXV:VPT) Headlines

No Headlines